

Getinge revises down outlook for 2022 – long-term financial targets unchanged

June 14, 2022

Key take-aways

- New outlook: organic net sales for 2022 in line with actual outcome in net sales for 2021
- Previous outlook: upper end of the range of 4-6% organic growth
- Getinge's financial position is expected to remain strong
- Getinge's financial targets through 2025 remain unchanged

Main reasons for new outlook

- Mild flu season – impacting sales of products for ECMO-therapy negatively
- Reduced production of COVID-19 vaccines
- Supply chain disruptions
- Russia's invasion of Ukraine

Getinge's financial targets through 2025 remain unchanged

- Organic net sales: 4-6% annual growth on average
- Adj EPS: >10% annual growth on average
- Adj EBITA margin 2025 as an outcome of the two targets: >21%

Q&A



GETINGE

PASSION FOR LIFE

Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.